HemaMax™, a Recombinant Human Interleukin-12, Is a Potent Mitigator of Acute Radiation Injury in Mice and Non-Human Primates

HemaMax, a recombinant human interleukin-12 (IL-12), is under development to address an unmet medical need for effective treatments against acute radiation syndrome due to radiological terrorism or accident when administered at least 24 hours after radiation exposure. This study investigated pharmac...

Descripción completa

Detalles Bibliográficos
Autores principales: Basile, Lena A., Ellefson, Dolph, Gluzman-Poltorak, Zoya, Junes-Gill, Katiana, Mar, Vernon, Mendonca, Sarita, Miller, Joseph D., Tom, Jamie, Trinh, Alice, Gallaher, Timothy K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286478/
https://www.ncbi.nlm.nih.gov/pubmed/22383962
http://dx.doi.org/10.1371/journal.pone.0030434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286478/
https://www.ncbi.nlm.nih.gov/pubmed/22383962
http://dx.doi.org/10.1371/journal.pone.0030434

Ejemplares similares